Navigation Links
Karolinska Development and Kurma Biofund to Enter Strategic Partnership
Date:6/29/2010

STOCKHOLM, June 29, 2010 /PRNewswire/ -- Karolinska Development AB and Kurma Biofund have entered into a strategic partnership, with the purpose to identify co-investment opportunities in the life science area in the Nordic region and other selected parts of Europe.

The Karolinska Development and Kurma Biofund combination will increase the possibilities for early life science investments in world class science. The strategic Karolinska Development and Kurma Biofund partnership will further contribute to cross European investments.

Conny Bogentoft, CEO Karolinska Development:

"We are excited to broaden our co-investor network for early stage financing. With Kurma we also add a broader dealflow outside of Scandinavia and add a competent partner to our network."

Thierry Laugel, joint Managing Partner Kurma Biofund:

"With Karolinska Development, Kurma is proud to add such an eminent group to the very selective network of partners around Europe. We are currently looking at a number of co- investment opportunities that would clearly exemplify the complementarities and synergies between our two groups."

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique business model, the company cost efficiently guides the commercialization of world class life science innovations. Since its inception in 2003, Karolinska Development has built a portfolio of some 40 companies. Among the company's projects, 12 candidate drugs are undergoing clinical trials and it is estimated that a total of 21 substances have first-in-class potential. http://www.karolinskadevelopment.com

About Kurma Biofund

Kurma Biofund is a new venture capital fund based in Paris and dedicated to innovations in Life Sciences and Healthcare. The fund has a unique positioning based on financing assets with near term realizations (3 to 5 years) for both technology transfer projects and mature projects. Kurma relies on very high quality investment opportunities generated through a network of partnerships in France and abroad with leading research institutes and a strong experienced team combining managing partners, venture partners and a strong network of scientific experts. Kurma Biofund I has closed a first round of financing of 50 million euros on the 24th November 2009. http://www.kurmabiofund.com

    For further information, please contact:

    Karolinska Development
    Conny Bogentoft: +46(0)-706-88-61-43
    conny.bogentoft@karolinskadevelopment.com

    Kurma Biofund
    Thierry Laugel : +33(0)1-58-50-91-09
    Thierruy.laugel@kurmabiofund.com



'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development and Uminova Invest Sign Co-operation Agreement
2. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
3. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
4. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
5. Karolinska Development Closes Fully Subscribed New Share Issue
6. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
7. Forza Silicon Announces High Dynamic Range CMOS Sensor Development
8. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
9. Artificial Pancreas can Prevent the Development of Hypoglycemia
10. aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
11. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, ... development, announces the launch of a new NTA biosensor chip for use with ... study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant ...
(Date:7/18/2017)... Basel, Switzerland (PRWEB) , ... July 18, 2017 ... ... for R&D, today announced that Merck, a leading science and technology company, has ... develop innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. ...
(Date:7/18/2017)... ... July 18, 2017 , ... Blood centers traditionally see a dangerous drop ... summer is a struggle for community blood centers as high schools are out and ... of Commerce is teaming up with the South Texas Blood & Tissue ...
(Date:7/18/2017)... ... July 18, 2017 , ... Recently recognized by CIO ... announces the migration of its flagship cloud-based product Planet Life Cycle – a ... work management system that merges strategic and financial planning with execution. The solution ...
Breaking Biology Technology:
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
Breaking Biology News(10 mins):